In March 1993, the World Health Organization (WHO) desconsistent efficacy (Ç80%) in preventing extrapulmonary TB ignated tuberculosis (TB) a global public health emergency. In (TB meningitis and miliary TB) in infants and children. Two the United States, the transient increase in the incidence of explanations have been offered for the differential effectiveness TB coupled with the emergence and nosocomial spread of in children and adults. The finding that efficacy is most apparent multidrug-resistant disease caused alarm and an outpouring of shortly after BCG vaccination may reflect the fact that protecresources to support TB control and research. The failure to tive immunity is only transitory. Alternatively, vaccination with achieve global control of TB stems largely from impediments BCG may not prevent primary infection following exposure to to the implementation of existing effective measures; these virulent M. tuberculosis but abort hematogenous dissemination. impediments, in turn, are economic, political, and behavioral
In this case, BCG would be most effective in averting extrapulrather than strictly biologic. Nonetheless, renewed interest and monary disease, including meningitis and miliary disease in recent progress in basic research on the microbiology and biochildren. If BCG efficacy is expressed through prevention of chemistry of Mycobacterium tuberculosis, host defenses bacillemia, vaccination also would be less effective in areas of against the organism, and the pathogenesis of TB is expected high transmission, where reinfection and progressive primary to accelerate development of interventions that will facilitate TB may be more relevant to the pathogenesis of pulmonary TB control. The current sequencing of the genome of M. tuber-TB than reactivation of latent foci. In fact, the lack of effectiveculosis, likewise, will represent a quantum leap forward in ness of BCG as a vaccine in certain geographic areas, particuunderstanding the organism and has tremendous potential to larly near the equator, is consistent with this thesis. lead to new interventions.
Ideally, a vaccine to prevent TB would confer lifelong proThis review will focus on current understanding of the hutection. Is this feasible? A related question is, Does natural man immune response to M. tuberculosis infection and disease infection with virulent M. tuberculosis confer lifelong immuand its potential implications for new approaches that will nity? In a study of persons known to be tuberculin-reactive 19 facilitate TB control.
years previously, we demonstrated excellent retention of skin test reactivity and in vitro evidence of circulating PPD (purified protein derivative)-reactive memory immune T cells [2] . This Protective Immunity and an Improved Vaccine high level of retained sensitization could result from repeated breakdown of infectious foci with in situ boosting. In fact, the Bacille Calmette-Guérin (BCG) is an attenuated strain of high incidence of reactivation TB in persons coinfected with Mycobacterium bovis first administered to humans as a vaccine human immunodeficiency virus type 1 (HIV-1) supports this to prevent TB in 1921. At that time, there was no knowledge contention, as will be discussed. of the protective immune response required to prevent TB. The
It is the persistence of the infectious agent in tissue and the rationale for the use of BCG as a vaccine was that an attenuated capacity for in vivo boosting that most likely accounts for organism would provide immunity against virulent challenge through cross-reactive immunogenic determinants. This emthe strong, sustained immunogenicity resulting from natural piric notion, although the basis for the eradication of smallpox infection. The persistence in tissues is a property of virulent and control of other viral diseases, may not be entirely relevant strains of M. tuberculosis. The latent focus of infection with for a facultative intracellular organism such as M. tuberculosis.
virulent M. tuberculosis provides not just the basis for boosting Durability of protection. The efficacy of BCG in the pre-DTH responses, but also the substrate for reactivation diseases. vention of pulmonary TB has shown considerable variation in
In turn, the limited efficacy of BCG as a vaccine could reflect different populations and trials [1] . There has, however, been overattenuation and diminished capacity for replication and persistence. This creates a ''Catch 22'' situation-the requirement for development of a vaccine strain with sufficient virulence to evoke lifelong protection but not enough virulence to with BCG followed by boosting, possibly with a subunit vac-IFN-g and also induces NK cells to produce this cytokine, which is key to protective immunity in the mouse. cine.
Basis for protective immunity. Understanding the immunoIn humans, the remarkable susceptibility of patients with AIDS to TB has demonstrated the critical role of CD4 lymphologic basis for protective immunity would provide a means for screening of potentially protective antigens and also a surrogate cytes in protective immunity. The dually infected individual (PPD skin test-positive, HIV-1-infected) in most cases is inmarker for rapid evaluation of the potential efficacy of a new vaccine. The natural history of M. tuberculosis infection indifected with M. tuberculosis before HIV-1 and has a 170-fold increased risk (5%-10%/year) of reactivation TB. This indicates that the emergence of delayed-type hypersensitivity (DTH) and presumably specific acquired resistance is associcates, somewhat surprisingly, that in the absence of immunosurveillance by CD4 cells, 5%-10% of persons with latent foci ated with control of the initial infection in 95% of normal hosts; the other 5% develop progressive primary TB. In addition, 5%
of TB have the potential to break down and reactivate each year. Therefore, the CD4 cell axis has a previously unrecogof infected persons eventually will reactivate latent pulmonary or extrapulmonary foci. It appears, therefore, that protective nized role in maintaining the inactivity of latent foci through active immunologic surveillance. In fact, ''latency'' may be a immunity results in the initial containment of endogenous infectious foci in most immunologically intact humans. Ideally, DTH to PPD could be used as a surrogate marker engage in major histocompatibility complex (MHC) class II-restricted killing of antigen-presenting cells infected with of protection. Unfortunately, although DTH and protective immunity emerge in parallel following primary infection with M. tuberculosis or pulse-exposed to soluble antigens [12] . The relative importance of cytokine production versus cytotoxic T M. tuberculosis, analysis of BCG trials indicates that DTH is not predictive of protection [4] . Abundant experimental data lymphocyte activity in the protective function of CD4 lymphocytes is unclear. also demonstrate that DTH and protective immunity are dissociable phenomena, elicited by different antigens and vaccines Two approaches have been taken to identify the cytokines that mediate protective immunity: characterization of the cyto-(as will be discussed below) and effected by different populations of lymphocytes.
kine milieu at a local site of effective immunity, and identification of cytokines that activate intracellular killing by mononuIn experimental murine models, CD4 lymphocytes, CD8 lymphocytes, and gd T cells each play a role in protective clear phagocytes. Pleural TB self-cures. The pleural fluid and the contained mononuclear cells show a biasing toward overeximmunity in the relative order: CD4 ú CD8 ú gd T cells. A recent study indicates that gd T cells, in fact, have little role pression of IFN-g, IL-2, and IL-12, with depressed expression of IL-4, the latter only seen at the mRNA level [12] . This in the protective immune response of mice to low-dose aerosol challenge [5] . They appear, however, to limit the trafficking pattern resembles dominance of Th1 versus Th2 CD4 cells in the murine paradigm. Th1 CD4 T cells produce IL-2 and of potentially injurious inflammatory cells to pulmonary granulomas. At the cytokine level, elegant experiments in mice with IFN-g and promote cell-mediated immunity. Th2 CD4 T cells produce IL-4, IL-5, and IL-10 and promote humoral immunity. genetically disrupted cytokine genes or treated with neutralizing anticytokine antibodies indicate that both interferon IL-12 drives differentiation of uncommitted Th0 cells into the Th1 pathway. Th1 and Th2 cytokines cross-regulate. For exam-(IFN)-g and tumor necrosis factor (TNF)-a are essential for protection [6] [7] [8] . Inducible nitric oxide (NO) synthase and NO ple, as will be seen, IL-10 can depress IFN-g production. Studies of the capacity of cytokines to activate intracellular also are required for bacterial killing [9] . In fact, the role of TNF-a and IFN-g may be partly to activate this effector pathgrowth inhibition (not to mention killing) of M. tuberculosis by human mononuclear phagocytes have failed to show conway in murine mononuclear phagocytes. Exogenous interleukin (IL)-12 transiently increases murine resistance to M. tuberculovincing activity of IFN-g. Rather, TNF-a and transforming growth factor (TGF)-b are induced by infection of mononusis [10] and increases survival [11] , although no effects are seen in mice with T cell deficiencies or disrupted IFN-g genes.
clear phagocytes with M. tuberculosis and function in autocrine pathways. TNF-a has a positive and TGF-b has negative ef-IL-12 promotes differentiation of CD4 cells that produce fects on limiting intracellular growth of the avirulent strain of Once a consensus emerges as to the identity of protective antigens, the next issue is their formulation as a vaccine. There M. tuberculosis, H37Ra, in human monocytes [13] . As noted, in contrast to murine models, IFN-g does not display macroare potential advantages for each of subunit vaccines, DNA vaccines, recombinant BCG overexpressing selected antigens, phage-activating factor activity against M. tuberculosis in humans. Two explanations have been offered. First, ingestion of and M. tuberculosis of attenuated virulence. Vaccination with BCG followed by a boost with a subunit vaccine also deserves M. tuberculosis may induce deactivating cytokines that interfere with the action of IFN-g. Indeed, some enhancement of further consideration. In addition to being effective, a new TB vaccine will need to be responsive to the issue of safety, the macrophage-activating factor activity of IFN-g is observed in the presence of neutralizing antibody to TGF-b [14] . Second, particularly in the HIV-1-infected host. It is quite apparent that a subunit or killed vaccine would be ideal. Some questions the chief activity of IFN-g in resistant species, such as the mouse, is to induce NO production. This mechanism is not have been raised about the safety of DNA vaccines, but their development for prevention of a number of infectious diseases, operant or expressed more stringently in susceptible species, such as humans and guinea pigs.
including HIV-1 infection, makes it likely that the generic concerns will be addressed before a TB-specific DNA vaccine The relevant product(s) of sensitized CD4 lymphocytes that mediate protective immunity in humans, therefore, is uncertain.
is ready for human trials. It is the attenuated M. tuberculosis auxotrophic mutants, for example, that are likely to incite the Nonetheless, blastogenesis and the production of cytokines such as INF-g and IL-2 are convenient readouts for the antimost controversy. Genetic safeguards may be helpful in gaining support for human trials with auxotrophic mutants. Efforts are genic repertoire of CD4 cells and well may reflect recognition by the CD4 population that is critical to protection.
underway to produce double mutations that will make reversion to a virulent phenotype more unlikely and to remove the antibiProtective antigens of M. tuberculosis. Immunization of mice with live M. tuberculosis induces protection and DTH, otic resistant cassette. A practical issue concerns the ethics of testing new vaccines. whereas heat-killed organisms induce DTH only [15] . This experimental observation has sparked interest in antigens reAs vaccination with BCG provides protection of infants and children against the lethal forms of extrapulmonary TB, it may leased or secreted by viable mycobacteria into culture filtrates as vaccine candidates. The antigenic repertoire of humans is be unethical to conduct a trial in newborns in which a new vaccine is compared with BCG. Alternative study designs, such surprisingly diverse and heterogeneous, with recognition of multiple culture filtrate antigens. It is possible, nonetheless, as the vaccination or revaccination of adult populations with a high incidence of TB, clearly will be required. The perforthat one or a few antigens could elicit a protective immune response. Current focus is on two antigens, ESAT-6 and the mance of trials in BCG-immunized adults in geographic areas in which BCG has failed to confer immunity has particular 30-kDa a or 85B antigen.
ESAT-6 is a low-molecular-mass product of early culture filappeal.
Surrogates for protective immunity. The Chingleput trial trates that induces IFN-g-producing T cells in immunized mice [16] and guinea pigs [17] . The 85B antigen is recognized by T of BCG vaccination in South India followed ú250,000 vaccinees for 20 years and ultimately showed no clear efficacy. Idecells from most M. tuberculosis-infected persons but not TB patients [18] . Further, immunization of guinea pigs with the 85B ally, surrogate markers of the protective immune response would permit rapid preliminary evaluation of efficacy in small antigen confers protection against virulent challenge [19] . On the other hand, immunization of mice with culture filtrate antigens to medium-sized phase II trials. This would allow selection of the most promising from among competing candidate vaccines induced protective immunity that was not sustained at the same level as that induced by a live vaccine [20] . Multiple antigens were and the optimization of vehicles, adjuvants, schedules, etc. It is true, however, that most existing effective vaccines were recognized during the initial expression of acquired immunity. In fact, immunization of mice with plasmid DNA constructs that developed without surrogate end points. The natural history of TB and extraordinary costs for an efficiency trial in terms of encode the 85A antigen conferred protection [21] , as did plasmid DNA that encoded the 65-kDa heat-shock protein and the 36-resources and time almost require, nonetheless, that some criteria be applied before committing to a phase III trial of a new kDa proline-rich antigen [22] . Epitope mapping of the a antigen in humans reveals that the dominant T cell epitopes demonstrate vaccine. Characterization of surrogates for vaccine efficacy in humans ''promiscuous reactivity,'' that is, donors with different MHC class II demonstrate responses, a property desirable for a vaccine is not a simple and straightforward task. Demonstration of protection in animal models is helpful, but may not be suffi- [23] . Similarly, individual epitopes of ESAT-6 are recognized by 25%-35% of all culture filtrate-reactive T cells recruited to the cient, to establish likely efficacy in humans. Clearly, available experimental models have their shortcomings. They do not site of infection in a mouse model [24] . Nonetheless, rather than individual epitopes and purified antigens, the protective immune adequately model reactivation TB, nor have they been used to address the potential for vaccination of infected persons. In response appears more and more likely to represent a summation of reactivity to a large number of antigens, so a vaccine will need fact, in animal models, BCG is the most potent of the vaccine candidates evaluated to date. to be multivalent. Immunoregulation and Cytokine Therapy ologic studies that prospectively establish the association of a proposed marker with resistance to the development of TB.
Insights into potential surrogates for protective immunity also derive from comparative in vitro studies of tuberculin Another approach would be to demonstrate that the surrogate marker of interest was induced by administration of an effective reactivity in skin test-positive ''resistant'' persons and ''susceptible'' patients with TB. Direct study of the diseased patient immunotherapy. Neither approach, however, addresses the issue of whether the immune response that contains the initial is, however, more directly relevant to pathogenesis and immunotherapy. infectious focus is relevant to long-standing protection and immunologic memory. A third approach, genetic, is considered
Regulation of the systemic immune response. The profile of systemic immune reactivity in patients with TB is one of below. Ultimately, the validity of any proposed surrogate will in fact be corroborated in a phase III trial with clinical end depressed tuberculin DTH, depressed in vitro PPD-stimulated blastogenesis, and expression of IL-2 and IFN-g [28] . The points such as vaccine efficacy.
depression of blastogenesis extends to nonmycobacterial antigens, although the defect in IL-2 production demonstrates more Immunogenetics of TB selectivity. There is concurrent elevation of IgM, IgG, and IgE specific for culture filtrate antigens as well as polyclonal B cell Epidemiologic data derived from twin studies clearly indicate that the susceptibility to TB has genetic determinants.
activation [29] . This pattern of increased B cell and depressed T cell function resembles experimental paradigms in which Studies of the association between HLA and TB generally have resulted in variable conclusions. DR2 was, however, associated there is an excess of Th2 relative to Th1 T cells and cytokines. Understanding of immunoregulation in human TB has adwith increased risk of progression to advanced pulmonary disease [25] . It is the DRB1*1501 allele that is associated with vanced beyond that of many other infectious diseases. The data indicate a novel regulatory mechanism. The response of advanced disease and failure to respond to drug therapy, whereas the DRB1*1502 allele was associated with decreased peripheral blood mononuclear cells (PBMC) to PPD is depressed by monocytes that overproduce inhibitory cytokines. risk [26] . Recent interest also has focused on the role of polymorphisms in cytokine promoters (e.g., TNF-a) and cytokine
The apparent restriction of the specificity of monocyte-dependent suppression to mycobacterial antigens results from the receptors (e.g., IFN-gR) in susceptibility to mycobacterial disease. The sequencing of both the human and M. tuberculosis unique ability of these antigens to stimulate expression of inhibitory cytokines. PPD is not just a stimulus for T cells but, genome, development of efficient approaches to screen the genome for disease susceptibility genes, and availability of in fact, a direct stimulus for monocytes activated in situ to overexpress IL-1, IL-6, IL-10, TNF-a, and TGF-b [30] . IL-10 suitable human populations for evaluation promise rapid progress in defining human susceptibility genes. Identification of and TGF-b function as cross-modulatory cytokines depressing blastogenesis and IFN-g production by T cells [31] . These the pattern of immune responses in subjects with the susceptible versus the resistant genotype also may provide insights into cellular interactions are displayed in figure 1 . Recent studies have addressed the relevant mycobacterial protective immunity and avenues for immunotherapy.
Studies of the genetics of resistance to BCG in the mouse stimuli and the mechanism by which they activate mononuclear phagocytes. PPD consists of proteins and nonprotein constithave led to characterization of the BCG resistance gene (NRAMP) as well as a human equivalent on chromosome 2q.
uents. LAM is the major cell wall lipoglycan of M. tuberculosis and an important constituent/contaminant of PPD. LAM deRecent studies suggest, however, that the BCG gene does not affect resistance of mice to virulent M. tuberculosis [27] . Famrived from the virulent strain H37Rv induces little TNF-a production compared with avirulent rapidly growing mycobacteria, ily studies should determine whether the BCG gene has a role in human susceptibility and resistance. Other potential loci such but LAM from virulent organisms retains the ability to induce TGF-b expression that is comparable in magnitude to that of as the MHC deserve reexamination using current approaches. months after completion of treatment) (Hirsch CS, personal communication). Increased expression of IL-10 and TGF-b by PPD-stimulated monocytes is a by-product of immune activation that reverses slowly during the treatment of pulmonary TB. Expression of the immunosuppressive cytokines is more pronounced in far-advanced than moderately advanced pulmonary TB and virtually nil in patients with minimal disease. The addition of exogenous IL-12 to cultures normalizes PPDstimulated IFN-g production. It is not clear, however, whether this is the result of reversing the defect so that CD4 cells produce normal amounts of IFN-g or, as may be more likely, bypassing the defect by stimulating IFN-g production by NK and other non-CD4 cell populations. Initial studies in HIVinfected TB patients also indicate profound suppression of IFN-g responses [37, 38] , a negative regulatory role for IL-10 [37, 39] , and restitution by IL-12 [37, 39] . ducted than studies of local immunity. The goal of immunotherapy is, however, to activate protective immunity at local sites of disease. Therefore, it is essential to address the question of the relevance of studies of the blood to the local immune avirulent organisms [32] . Therefore, the bias toward expression of TGF-b and the spontaneous expression of this cytokine by response. Initial studies of the pulmonary immune response by bronchoalveolar lavage indicate that there is an alveolitis blood monocytes and in granulomas [33] may relate to nonprotein constituents of the tubercle bacillus.
comprising predominantly T lymphocytes and macrophages, with an increase in immature peroxidase-positive cells [40] Culture filtrate proteins also induce cytokine production by mononuclear phagocytes, but in this case, there is balanced ( figure 2 ). The local inflammatory response appears to develop by chemotaxis of circulating T cells and monocytes to the site expression both of stimulatory and inhibitory cytokines. The 85B antigen, a major culture filtrate protein and candidate for of disease. Therefore, understanding the function and regulation of blood mononuclear cell responses to PPD is extremely protective antigen, induces expression of cytokines by binding to fibronectin on the monocyte cell surface [34] . A 58-kDa relevant to the understanding of the local immune response as well as selection of immunotherapy. Preliminary functional culture filtrate protein [35] with glutamate synthetase activity [36] is another and more potent inducer of cytokines. The studies indicate, however, that alveolar lymphocytes from patients with tuberculosis show increased PPD-induced blastoinduction of cytokines by mycobacterial constituents may be a factor in the immunopathogenesis of TB. The proteins that genesis and an increased frequency of IFN-g-producing cells. Also, alveolar macrophages from TB patients appear to fail to induce cytokines also may possess an adjuvant-like property that enhances their immunogenicity and thus is potentially relesuppress PPD-stimulated blastogenesis (Schwander SK, personal communication). Obviously, further studies will be vant to their use as vaccines.
Depressed tuberculin skin test responses and the suppressed needed to clarify the relationship between regulation of the local and systemic immune response in tuberculosis. It should PPD-stimulated blastogenesis are transient phenomena, largely reversed within 1 month of the start of treatment. Recent data be noted that it is the systemic response that is relevant to protective immunity induced by vaccines. On the other hand, indicate, however, that cytokine production is regulated differently. The depressed PPD-stimulated production of IFN-g perimmunotherapy of active disease ideally is directed at enhancing the local response at the site of disease. sists for at least 12 months after the diagnosis of TB (and 6 
Implications for immunotherapy. The potential goals of
Purified recombinant cytokines that are potentially available and relevant as immunotherapy for TB include IL-2, IFN-g, immunotherapy are 2-fold: in multidrug-resistant disease, as an adjunct to available chemotherapy in an attempt to improve and IL-12. Recent data with low-dose IL-2 immunotherapy suggest accelerated clearance of acid-fast bacilli from the spuon the prevailing 50% cure rates, and in drug-sensitive TB, to shorten the duration of treatment by bolstering the immune tum in drug-resistant TB [41] . IFN-g has been used with some success to treat drug-resistant Mycobacterium avium disease in response, thereby accelerating the eradication of persisting organisms. The traditional approach to immunotherapy of TB non-AIDS patients [42] . IL-12 is of particular interest because, as noted, it induces expression of IFN-g by NK cells and also would be to administer the cytokines that are essential to protective immunity. There are several problems with this apthe differentiation of Th0 from Th1 cells. Exogenous IL-12 achieves a remarkable reconstitution of PPD-stimulated proach. First, the cytokines most relevant to protective immunity in humans are unknown. Data from murine models may IFN-g production in PBMC from TB patients (Hirsch CS, personal communication). The use of recombinant cytokine be misleading, as the cytokines of interest function to activate inducible NO, which has not been shown convincingly to be therapy, although promising for drug-resistant disease, may be too difficult to administer, toxic, and expensive for use in the a mediator of macrophage effector function in humans. Second, given the bias in TB toward immunosuppression, the provision treatment of drug-sensitive disease. Another potential approach would be to administer pharmacologic cytokine inducers as of exogenous cytokines may merely ''fuel the fire'' by activatappropriate agents became available. ing more endogenous expression of suppressive mediators. In such a case, the main result of cytokine therapy would be Inhibition of negative regulators deserves further consideration as immunotherapy for TB, particularly as naturally octoxicity.
curring inhibitors of TGF-b, L-decorin, and latency-associated with HIV-1 through NFkB mechanisms. Moreover, two markers of macrophage activation, serum neopterin and TNF-aR-II, protein have been described. Initial studies indicate that both L-decorin and latency-associated protein increase PPD-stimuare increased in TB-HIV coinfection and represent independent predictors of poor prognosis [49] . To complete the story, monolated blastogenesis and IFN-g production by PBMC from patients with pulmonary TB [43] . Blocking the negative cytokine cytes from patients with TB show increased susceptibility to a productive infection with HIV-1 [48] . M. tuberculosis and PPD mediators could be used as a sole immunotherapeutic strategy or in addition to providing a positive signal.
also induce HIV replication in the latently infected U1 cell line [50] . Another approach would be to modulate the immune response by administering a therapeutic vaccine. Uncontrolled
Although other opportunistic infections also may shorten survival in HIV, TB may be unique because its impact on HIV trials and recently a controlled trial suggest that administration of heat-killed Mycobacterium vaccae as a therapeutic vaccine is exacted at a higher CD4 cell count and for prolonged periods, when there is more to lose in terms of survival. Further, activaaccelerates sputum bacteriologic conversion and provides clinical benefit in pulmonary TB. It has been proposed that tion of T cells and macrophages and expression of TNF-a are essential features of the immunopathogenesis and protective M. vaccae shifts the T cell response from a Th2 to a Th1 pattern. M. vaccae is easy to prepare and administer, appears immune response of TB but may be deleterious as regards containment of HIV-1. to be nontoxic, and should be inexpensive. Clearly, further study is warranted. In fact, controlled clinical trials are in progTrials of cytokine inhibitors. The obvious approach to averting the morbidity of TB-HIV coinfection is prevention, ress in South Africa and Uganda. If M. vaccae is effective as immunotherapy, parallel studies of immune reactivity may although this may prove difficult to accomplish in developing countries. Cytokine inhibitors also may have a role as an adidentify surrogates for an effective or protective (or both) response.
junct to chemotherapy, particularly if viral replication increases during treatment of the TB. Both thalidomide, a specific TNF-a inhibitor, and pentoxifylline, a nonspecific inhibitor, TB-HIV Interactions have undergone controlled trial in TB-HIV. The results indicate a decrease in virus load and possible clinical benefit (increase TB and HIV-1 often occur in the same geographic area, in the same person, and even in the same cell. It is not surprising, in weight gain for thalidomide, increased Karnofsky score and hemoglobin level for pentoxifylline) [52] [53] [54] . The impact on therefore, that they have important and bidirectional interactions. The impact of HIV on TB is profound. As indicated, the survival of these and possibly more potent cytokine inhibitors needs to be assessed. immunosuppression of HIV dramatically increases the risk of reactivation of a latent focus of infection and progression of primary infection. The rapid progression of primary infection Predictions to infectious TB catalyzes the spread of the strains of M. tuberculosis that are prevalent in the community, including multiThe allure of improved vaccines, immunotherapy, and cytokine inhibitors is apparent. The question is, How close are we drug-resistant TB. HIV-1 also alters the clinical expression of TB, as there is less cavitary disease and more atypical, (and how great will the impact be on TB control)? It is easy to be skeptical, as the application of immunotherapy to infectious disseminated, and extrapulmonary manifestations.
The impact of TB on HIV may prove to be equally profound. diseases has been talked of since the time of Shaw: ''Stimulate the phagocytes.'' TB in the HIV-infected is associated with shortened survival not attributable to death from TB [44, 45] . Rather it appears
In fact, the era is upon us. Controlled trials of immunotherapy for TB are in progress or planning stages for M. vaccae that patients are dying of progressive immunodeficiency. Does TB accelerate the course of HIV? Recent data support this as a therapeutic vaccine and for cytokine therapy with recombinant IL-2. Likewise, controlled trials of the cytokine inhibitors notion. TB-HIV coinfection is associated with a higher plasma virus load (RNA) than is found in CD4 cell-matched HIVpentoxifylline and thalidomide have been completed in patients with TB-HIV coinfection, and a trial of prednisolone has infected controls. Moreover, virus load actually increases during the course of treatment of the TB [46] . The development started. Of these interventions, only the widespread use of a safe and inexpensive agent could impact meaningfully on TB of TB also is associated with accelerated rates of decline in numbers of CD4 lymphocytes, a process that continues as the control.
Of course, the single most valuable intervention would be a TB is treated [47] .
The basis for increased viral replication and more rapid devaccine that is effective in preventing M. tuberculosis infection as well as disease and in aborting progression from infection cline in numbers of CD4 cells in TB-HIV coinfection may relate to activation of cells that harbor latent HIV. In fact, CD4 to disease. Identifying the optimal vaccine and schedule, validating immunologic surrogates as trial end points, and concells and monocytes display surface markers of activation [48] , and there is increased production of TNF-a. Serum TNF-a ducting a trial to demonstrate superior efficacy relative to BCG vaccine separately and together pose a formidable challenge, also is increased. TNF-a is known to activate latent infection
